article_snippet: The praise follows yesterday’s annual meeting of the American Academy of Dermatology, where US bio-tech company Topokine Therapeutics presented details of a trial of 90 patients, aged between 40 and 70, who applied the cream once a day to their under-eye area for ten weeks.
article_snippet: a trial of 90 patients, aged between 40 and 70, who applied the cream once a day to their under-eye area for ten weeks was double-blind and placebo-controlled, meaning that neither the participants nor the researchers knew which patients belonged to the control group or the test group.
article_snippet: Dr Michael Singer, Topokine’s chief scientific officer, said: ‘A one-grade improvement may sound small, but it is a meaningful change.
article_snippet: Participants said Participants felt Participants looked more youthful, more attractive and more well rested after treatment.
highlights_snippet: It was tested on 90 patients who applied cream once a day for ten weeks .
  